204 related articles for article (PubMed ID: 1346236)
41. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
42. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A.
Yu D; Shi D; Scanlon M; Hung MC
Cancer Res; 1993 Dec; 53(23):5784-90. PubMed ID: 7902209
[TBL] [Abstract][Full Text] [Related]
43. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.
Zhang X; Silva E; Gershenson D; Hung MC
Oncogene; 1989 Aug; 4(8):985-9. PubMed ID: 2569708
[TBL] [Abstract][Full Text] [Related]
44. Identification of a candidate oncogene SEI-1 within a minimal amplified region at 19q13.1 in ovarian cancer cell lines.
Tang TC; Sham JS; Xie D; Fang Y; Huo KK; Wu QL; Guan XY
Cancer Res; 2002 Dec; 62(24):7157-61. PubMed ID: 12499249
[TBL] [Abstract][Full Text] [Related]
45. Transfected neu oncogene induces human prostate cancer metastasis.
Zhau HY; Zhou J; Symmans WF; Chen BQ; Chang SM; Sikes RA; Chung LW
Prostate; 1996 Feb; 28(2):73-83. PubMed ID: 8604395
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor.
Meden H; Kuhn W
Eur J Obstet Gynecol Reprod Biol; 1997 Feb; 71(2):173-9. PubMed ID: 9138962
[TBL] [Abstract][Full Text] [Related]
47. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.
Buza N; Hui P
Genes Chromosomes Cancer; 2013 Dec; 52(12):1178-86. PubMed ID: 24123408
[TBL] [Abstract][Full Text] [Related]
48. Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Hakim AA; Barry CP; Barnes HJ; Anderson KE; Petitte J; Whitaker R; Lancaster JM; Wenham RM; Carver DK; Turbov J; Berchuck A; Kopelovich L; Rodriguez GC
Cancer Prev Res (Phila); 2009 Feb; 2(2):114-21. PubMed ID: 19174584
[TBL] [Abstract][Full Text] [Related]
49. [Overexpression of c-erbB-2 oncogene in primary ovarian cancers: incidence and prognostic significance in 243 patients].
Meden H; Marx D; Rath W; Kuhn W; Hinney B; Schauer A
Geburtshilfe Frauenheilkd; 1992 Nov; 52(11):667-73. PubMed ID: 1360438
[TBL] [Abstract][Full Text] [Related]
50. Human neu oncogene is expressed in endometrial but not in ovarian adenocarcinomas.
Garuti G; Genazzani AR
Cancer; 1991 Mar; 67(6):1713. PubMed ID: 1672104
[No Abstract] [Full Text] [Related]
51. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas.
Park JB; Rhim JS; Park SC; Kimm SW; Kraus MH
Cancer Res; 1989 Dec; 49(23):6605-9. PubMed ID: 2573419
[TBL] [Abstract][Full Text] [Related]
52. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma.
Nanni P; Pupa SM; Nicoletti G; De Giovanni C; Landuzzi L; Rossi I; Astolfi A; Ricci C; De Vecchi R; Invernizzi AM; Di Carlo E; Musiani P; Forni G; Menard S; Lollini PL
Int J Cancer; 2000 Jul; 87(2):186-94. PubMed ID: 10861472
[TBL] [Abstract][Full Text] [Related]
53. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
54. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1.
Kacinski BM; Carter D; Mittal K; Yee LD; Scata KA; Donofrio L; Chambers SK; Wang KI; Yang-Feng T; Rohrschneider LR
Am J Pathol; 1990 Jul; 137(1):135-47. PubMed ID: 1695482
[TBL] [Abstract][Full Text] [Related]
55. [The relation between prognosis and amplification of the c-erB-2 (HER-2/neu) proto-oncogene in ovarian carcinomas].
Fan QB; Bian ML; Huang SZ
Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):683-5, 710. PubMed ID: 7866905
[TBL] [Abstract][Full Text] [Related]
56. DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder.
Wood DP; Wartinger DD; Reuter V; Cordon-Cardo C; Fair WR; Chaganti RS
J Urol; 1991 Nov; 146(5):1398-401. PubMed ID: 1942310
[TBL] [Abstract][Full Text] [Related]
57. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
McKenzie SJ; DeSombre KA; Bast BS; Hollis DR; Whitaker RS; Berchuck A; Boyer CM; Bast RC
Cancer; 1993 Jun; 71(12):3942-6. PubMed ID: 8099528
[TBL] [Abstract][Full Text] [Related]
58. Involvement of tyrosine phosphorylation of p185(c-erbB2/neu) in tumorigenicity induced by X-rays and the neu oncogene in human breast epithelial cells.
Kang KS; Sun W; Nomata K; Morita I; Cruz A; Liu CJ; Trosko JE; Chang CC
Mol Carcinog; 1998 Apr; 21(4):225-33. PubMed ID: 9585252
[TBL] [Abstract][Full Text] [Related]
59. Decreased expression of the Id3 gene at 1p36.1 in ovarian adenocarcinomas.
Arnold JM; Mok SC; Purdie D; Chenevix-Trench G
Br J Cancer; 2001 Feb; 84(3):352-9. PubMed ID: 11161400
[TBL] [Abstract][Full Text] [Related]
60. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
Zhang Y; Yu D; Xia W; Hung MC
Oncogene; 1995 May; 10(10):1947-54. PubMed ID: 7761095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
